# **Interfacility Paramedic Transport Infusions**



Developed March 2025

| Medication Infusion Guidelines    |        | 42.A.1 |
|-----------------------------------|--------|--------|
| All Crystalloid Solutions.        |        |        |
| Antibiotics                       |        | 42.C.1 |
| Antivirals                        |        | 42.D.1 |
| Racemic Epinephrine               |        | 42.E.1 |
| Natural Colloids (Blood Products) |        | 42.F.1 |
| Alteplase (post Tenecteplase IVP) |        | 42.G.1 |
| Dopamine                          |        | 42.H.1 |
| Norepinephrine                    |        | 42.I.1 |
| Heparin Sodium                    |        | 42.J.1 |
| Nitroglycerin                     |        | 42.K.1 |
| Amiodarone                        |        |        |
| Diltiazem                         |        |        |
| Metoprolol (IVP)                  | 11. 11 | 42.N.1 |
| Magnesium Sulfate                 |        | 42.0.1 |
| Octreotide                        |        | 42.P.1 |
| Hydrocortisone Sodium succinate   |        | 42.Q.1 |
| Furosemide                        |        |        |
| Pantoprazole                      |        | 42.S.1 |
| Multivitamin Banana Bag           |        |        |
| Sodium Bicarbonate                |        |        |
| Vitamin K                         |        | 42.V.1 |

## **Medication Infusion Guidelines**

The medications listed in the following protocols are the only medications that EMS may transport at the Interfacility Paramedic and Expanded Scope level. This includes any medication in the ALS Protocol as well as additional, commonly transferred medications. Specific guidelines for each medication are listed in that protocol. General information is listed below. At any time if a crew member does not feel comfortable with the patient condition and the transport scenario, they need to relay their concerns to the hand off care providers, work to address the concerns, if not addressed, Medical Control may be contacted.

#### **GENERAL PATIENT CARE ORDERS:**

- 1. All medications, with the exception of Antibiotics, Antivirals, and Multi-vitamin Banana Bag, must be transported on a pump. The treating provider must be competent in the management of the pump, either via previous training, or just in time training prior to taking responsibility for patient care.
- 2. Routine ALS Care
- 3. Verify initial dose and infusion rate as well as total time at the transferring facility <u>prior to</u> departure.
- 4. **Monitor patient closely** en route.
- 5. Any other change in rate/dosage of the medication during interfacility transfer requires **Medical Control** order.
- 6. If perceived life-threatening reaction, infusion may be stopped while contacting Medical Control.

#### **ADDITIONAL REQUIREMENTS:**

This is an Advanced Scope of Practice Protocol. Only providers who have completed additional system training are authorized to perform. The protocol is only designed for patients who are being transferred from one medical facility to another.

A Medical Control Physician must be contacted prior to the EMS crew taking transfer of care of the patient if any of the following conditions apply:

- 1. Patient in hypotensive at the time of transfer.
- 2. An acute deterioration or change in the patient's status is noted.
- 3. Medications ordered are outside of the concentrations or infusion rates that are permitted by the current prehospital treatment protocols.
- 4. The prehospital provider has any concern that the provider's experience or abilities, or the available equipment, may not meet the patient's anticipated needs during the transport.

# All Crystalloid Solutions

#### **CLASS:**

1. Crystalloids

#### **ACTION:**

Increase Intravascular volume Replenish Electrolyte deficits

#### **INDICATION:**

- 1. Hypovolemia
- 2. Hemorrhage
- 3. Sepsis
- 4. Dehydration
- 5. Hemodynamic instability
- 6. IV medication delivery
- 7. Maintenance

#### **COMPLICATIONS/ADVERSE REACTIONS:**

1. Too fast infusion can produce a volume overload state

#### **PRECAUTIONS:**

- Hyperkalemia
- Cerebral edema
- Congestive heart failure patients
- Renal insufficiency patients

#### **SIDE EFFECTS:**

- Fluid overload
- Pulmonary edema
- Electrolyte imbalance
- Acid-base disturbances

#### **EQUIPMENT:**

• Varies based on patient diagnosis

#### **HOW SUPPLIED:**

• 250 mL, 500 mL and 1000 mL

#### DOSE:

• Rate determined by transferring physician



## **Antibiotics**

#### **CLASS:**

Antibiotic

#### **ACTION:**

• Treatment for known infection. Prophylactic measure for patient who may undergo surgical procedure or who has had recent exposure that indicates likelihood of resulting infection.

#### **INDICATION:**

- 1. Pre-existing diagnosed infection or suspected infection.
- 2. Exposure that creates likelihood of resulting infection.

#### **CONTRAINDICATION:**

1. Known allergy to the medication

#### **COMPLICATIONS/ADVERSE REACTIONS:**

- 1. Allergic reactions
- 2. Ototoxicity
- 3. Nephrotoxicity (aminoglycosides)

#### **PRECAUTIONS:**

1. Speed of infusion

#### SIDE EFFECTS:

• Localized reaction to infusion: redness/ burning at site of infusion.

#### **EQUIPMENT:**

• Antibiotic infusions may be administered by pump or by gravity set rate. Dial-a-flow devices can also be utilized.

#### **HOW SUPPLIED:**

Varies by antibiotic

#### DOSE:

• Dependent on the specific antibiotic.

- 1. Antibiotics need to be started 15 minutes or more before the start of the transport.
- 2. Verify infusion rate as well as total time at the transferring facility prior to departure.
- 3. Follow Anaphylaxis Protocol if needed for signs of allergic reaction and/ or shock.
- 4. If infusion is completed during transport, antibiotics should be discontinued, and line kept open by infusing 0.9% Normal Saline at TKO rate.

## **Antivirals**

#### **CLASS:**

• Antivirals

#### **ACTION:**

• Treatment for known infection. Prophylactic measure for patient who may undergo surgical procedure or who has had recent exposure that indicates likelihood of resulting infection.

#### **INDICATION:**

1. Suspected viral infection

#### CONTRAINDICATION

1. Known allergy to the medication

#### **COMPLICATIONS/ADVERSE REACTIONS:**

- 1. Allergic reactions
- 2. Ototoxicity
- 3. Nephrotoxicity (aminoglycosides)

#### **PRECAUTIONS:**

1. Speed of infusion

#### **SIDE EFFECTS:**

Localized reaction to infusion: redness/ burning at site of infusion.

#### **EQUIPMENT:**

• Antiviral infusions may be administered by pump or by gravity set rate. Dial-a-flow devices can also be utilized.

#### **HOW SUPPLIED:**

• Varies by medication

#### DOSE:

• Dependent on the specific antivirals.

## **Antivirals**

- 1. Antivirals need to be started 15 minutes or more before the start of the transport.
- 2. Verify infusion rate as well as total time at the transferring facility prior to departure.
- 3. Follow Anaphylaxis Protocol if needed for signs of allergic reaction and/ or shock.
- 4. If infusion is completed during transport, antivirals should be discontinued, and line kept open by infusing 0.9% Normal Saline at TKO rate.



# Racemic Epinephrine

#### **CLASS:**

• Alpha and beta agonist

#### **ACTION(S):**

• Enhances activity of both alpha and beta receptors

#### **INDICATIONS:**

- 1. Adult:
  - a. Asthma
- 2. Pediatrics
  - a. Bronchospasm, asthma
  - b. Croup

### CONTRAINDICATIONS/COMPLICATIONS/ADVERSE REACTIONS:

None listed

#### **PRECAUTIONS:**

1. Used with caution in patients with following conditions: heart disease, hypertension, diabetes, glaucoma, prostatic hyperplasia, psychiatric conditions, seizure disorder, thyroid disease

#### **SIDE EFFECTS:**

- Tachycardia
- Anxious feeling
- Hypertension

#### **HOW SUPPLIED:**

• 2.25% nebulized solution

## Racemic Epinephrine

#### DOSE:

- Adult:
  - a. Asthma: (hand bulb nebulizer) 1 to 3 inhalations of 2.25% (1 vial); may repeat in 3 hours as needed
- Pediatrics
  - a. Bronchospasm, asthma: (hand bulb nebulizer) Add 0.5 mL (1 vial) of 2.25% solution to nebulizer; 1 to 3 inhalations; may repeat dose after at least 3 hours if needed
  - b. Croup: Nebulization: 0.05 to 0.1 mL/kg (maximum dose: 0.5 mL/dose) diluted in 2 to 3 mL NS, may repeat dose every 15 to 20 minutes

#### **STANDING ORDERS:**

1. Any other change in rate/dosage of racemic epinephrine during interfacility transfer requires **Medical Control** order.

# Natural Colloids (Blood Products)

#### **CLASS:**

• Blood Components

#### **ADDITIONAL NAMES:**

- FFP
- PRBCs
- Platelets
- Clotting factors
- Albumin

#### **ACTION:**

Replace cells (fresh frozen plasma or packed red blood cells) needed by the body

#### **INDICATION:**

- 1. Hemorrhagic shock
- 2. Anticoagulant reversal
- 3. Symptomatic anemia

### **CONTRAINDICATION:**

1. Patient refusal

#### **COMPLICATIONS/ADVERSE REACTIONS:**

- 1. Transfusion reaction. Severe reactions will usually manifest during initial 50cc or less of infusion.
- 2. ABO incompatibility

#### **PRECAUTIONS:**

1. Too fast of infusion can produce volume overloaded state.

#### **SIDE EFFECTS:**

- Transfusion reaction
- Volume Overload

### **Blood Products**

#### **HOW SUPPLIED:**

- 250-300 mL per unit infusion
- Usually infused over 1- 3 hours

#### DOSE:

- 1 unit
- Rate based on situation

- 1. Blood infusions must be started at least 15 minutes before the transport AND at least 50 CC must be infused before the transport can begin.
- 2. Temperature must be taken every 15 minutes.
- 3. If perceived life-threatening reaction, infusion may be stopped while contacting Medical Control.
- 4. Tubing must be changed every 2 units or after every 4 hours of use. Tubing must be discarded immediately following completion of transfusion.
- 5. If receiving two separate blood products (RBC's and platelets), they must infuse through separate IV sites.
- 6. If signs of transfusion reaction, infusion should be stopped, and the tubing should be removed. Tubing and remaining blood should be transported to destination facility for evaluation.
  - a. Signs of a transfusion reaction include:
    - i. Temperature
    - ii. Hypertension/ Hypotension
    - iii. Dyspnea
    - iv. Rash
    - v. Itching
    - vi. Hives
  - b. Treat symptoms based on appropriate protocol which may include
    - i. Benadryl 25-50 mg IV
    - ii. IV Fluids
    - iii. Epinephrine 0.15-0.3 mg IM

## Alteplase (post Tenecteplase IVP)

#### **CLASS:**

• Thrombolytic

#### **ADDITIONAL NAMES:**

- Activase (Alteplase)
- Alteplase (Alteplase)
- TNKase (Tenectaplase)

#### **ACTION:**

• Dissolve clot in treatment of ischemic stroke.

#### **INDICATION:**

- 1. Ischemic Stroke-Alteplase and Tenecteplase.
- 2. Acute MI-Alteplase and Tenecteplase.
- 3. Unstable Pulmonary Embolism-Alteplase

#### **CONTRAINDICATION:**

- 1. Nasogastric Tube
- 2. Evidence/ suspicion of cerebral hemorrhage
- 3. Intracranial or intraspinal surgery, serious head trauma or previous stroke within last 3 months
- 4. History of intracranial hemorrhage
- 5. Uncontrolled hypertension (> 185mmHg Systolic, > 110 mmHg Diastolic)
- 6. Seizure at the onset of stroke
- 7. Active internal bleeding
- 8. Intracranial neoplasm, arteriovenous malformation, or aneurysm
- 9. History of Pradaxa use
- 10. Known bleeding diathesis including but not limited to:
  - a. Current use of oral anticoagulants or an International Normalized Ratio (INR) >1.7 or a prothrombin time (PT) > 15 seconds
  - b. Administration of heparin or Low Molecular Weight Heparin (Lovenox) within 48 hours preceding the onset of stroke and have an elevated partial thromboplastin time (aPTT) at presentation
  - c. Platelet count <100,000mm3

#### **COMPLICATIONS/ADVERSE REACTIONS:**

- 1. Bleeding
- 2. Reperfusion arrhythmias
- 3. Elevated temp
- 4. Hypotension
- 5. Anaphylactic Reaction

## Alteplase (post Tenecteplase IVP)

#### **PRECAUTIONS:**

- 1. Alteplase or Tenecteplase must be started within 4.5 hours of onset of symptoms.
- 2. Do not take blood pressure in the arm tPA is infusing in.
- 3. Patient must be NPO for 24 hours and until swallow study is done.

#### **SIDE EFFECTS:**

- Bleeding at venipuncture sites and other various sites
- Hematuria
- Intercranial hemorrhage

#### **HOW SUPPLIED:**

• Alteplase -100mg/100mL bedside premix for infusion

#### DOSE:

- Loading dose of 10% of total infusion given over 1 minute to be completed at transferring facility.
- Infusion of 0.9mg/kg to be infused over 60 minutes.

#### STANDING ORDERS:

1. If infusion is completed during transport, tPA should be discontinued and line kept open by infusing 0.9% Normal Saline at TKO rate.

#### **PEARLS**

While Tenecteplase (TNK) is used in the same patients, the administration of a single injection negates the need for EMS to transport with an ongoing infusion. Regardless the side effects, precautions, and standing orders above would also apply to the patient post Tenecteplase as they would for a patient post Alteplase.

# Dopamine

#### **CLASS:**

Sympathomimetic

#### **ACTION:**

• Alpha- and beta-adrenergic agonist, resulting in increased cardiac contractility and myocardial workload as well as peripheral vasoconstriction (both venous & arterial)

#### **INDICATIONS:**

- 1. Correction of hemodynamic imbalance in hypoperfusion syndromes other than volume deficit
- 2. Cardiac dysfunction due to AMI
- 3. Cardiac dysfunction due to CHF
- 4. Poor perfusion due to sepsis
- 5. Neurologically induced vasodilation (neurogenic shock)
- 6. Renal failure

#### **CONTRAINDICATIONS:**

- 1. Uncontrolled tachycardia
- 2. Ventricular irritability
- 3. Hypertension
- 4. Hypoperfusion from volume deficit

#### COMPLICATIONS/ADVERSE REACTIONS/SIDE EFFECTS:

- 1. Tachycardia
- 2. Hypertension
- 3. Ventricular irritability
- 4. Angina
- 5. Anxiety
- 6. Decreased peripheral perfusion
- 7. Tissue necrosis with infiltration of IV line

#### PRECAUTIONS:

Use with caution in the following patients:

- Children
- 2. Patients with occlusive vascular disease (or other types of peripheral vascular insufficiency)

#### **HOW SUPPLIED:**

- 400mg in 250mL D<sub>5</sub>W
- 800mg in 250 mL D<sub>5</sub>W

# Dopamine

#### DOSE:

Dopaminergic (renal) dose:
 Beta agonist (cardiac) dose:
 Alpha agonist (vasopressor) dose:
 2-5mcg/kg/min
 5-15mcg/kg/min
 >15mcg/kg/min

- 1. Verify patient's weight (in kilograms)
- 2. Verify concentration & dose, infusion rate as well as total time and vital sign parameters at the transferring facility prior to departure.
- 3. Incompatible with Sodium Bicarb. No IV push drugs can be administered through this line. Monitor patient closely for rhythm changes en route and repeat vitals signs *every 15 minutes*.
- 4. Monitor urine output (should be at least 25mL/hr)
- 5. Maximum infusion of Dopamine not to exceed 50mcg/kg/minute.

# Norepinephrine

#### **CLASS:**

• Sympathomimetic

#### **ADDITIONAL NAMES:**

Levophed

#### **ACTION:**

• Alpha adrenergic and some Beta-adrenergic agonist to cause peripheral vasoconstriction, increase blood pressure and increase heart rate to lesser degree

#### **INDICATION:**

- 1. Neurogenic shock
- 2. Septic shock
- 3. Hypotension refractory to other sympathomimetics

#### **CONTRAINDICATION:**

1. Hypotension from hypovolemia

#### COMPLICATIONS/ADVERSE REACTIONS:

1. Headache

#### PRECAUTIONS:

- 1. Alkaline solutions can deactivate.
- 2. Requires constant monitoring of blood pressure.
- 3. Extravasation can cause tissue necrosis.
- 4. Infusion rates > 20 mg/ min significantly increase risk of extravasation.

#### **SIDE EFFECTS:**

- Anxiety
- Palpitations
- Hypertension

#### **HOW SUPPLIED:**

- 4 mg/ 250 mL (typical)
- 8 mg/ 250 mL (double strength)

# Norepinephrine

#### DOSE:

- 0.5-40 mcg/ minute. Typical starting dose is 5 mcg/min. Max 40 mcg/min.
- 4 mg in 250 ml of D5W, giving a concentration of 15 mcg/mL (Typical)
- MEMS does **not** use weight-based dosing. If EMS responds for an inter-facility transport and finds dosing or concentrations other than as noted above, Contact Medical Control for orders.

- 1. Contact Medical Control if the heart rate is greater than 150 bpm or persistently less than 60 bpm or a SBP less than 90 for 2 consecutive readings 5 minutes apart.
- 2. Any change in rate/dosage of Norepinephrine during inter-facility transfer requires Medical Control Order. Typical titration orders would be increasing 2.5-5mcg/min every 5 minutes to maintain SBP>90mmHg.

# Heparin Sodium

#### **CLASS:**

Anticoagulant

#### **ACTION(S):**

• Functions as an anticoagulant by accelerating neutralization of activated clotting factors, hence inhibiting the clotting of blood and the formation of fibrin clots.

#### **INDICATIONS:**

- 1. Concurrent usage with administration of TPA in the acute MI patient
- 2. Treatment of pulmonary embolism and a-fib with embolization
- 3. Treatment of peripheral arterial embolism
- 4. Treatment of venous thrombi and its extension
- 5. Prevention of re-thrombosis or re-occlusion during MI after thrombolytic therapy

#### **CONTRAINDICATIONS:**

#### **Absolute:**

- 1. Severe thrombocytopenia
- 2. Uncontrolled active bleeding (except when known to be from DIC [disseminated intravascular coagulation])
- 3. Sensitivity to Heparin

#### Relative:

- 1. Any disease where risk of hemorrhage may be increased
- 2. Aneurysm
- 3. Severe hypertension
- 4. Diverticulitis or ulcerative colitis
- 5. Severe hepatic disease or renal disease
- 6. Sub-acute bacterial endocarditis
- 7. Following major surgery or lumbar puncture (spinal tap)

#### **COMPLICATIONS/ADVERSE REACTIONS:**

- 1. Local site irritation
- 2. Hypersensitivity
- 3. Anaphylactic reaction
- 4. Adrenal hemorrhage

# Heparin Sodium

#### **PRECAUTIONS:**

Use with caution in the following patients:

- 1. Pregnant patients
- 2. Alcoholics (due to decreased hepatic function)
- 3. Elderly (due to decreased hepatic & renal function and increased injury capability
- 4. Avoid IM injections or other procedures that may cause bleeding.
- 5. Move patients gently to avoid bruising or bleeding

#### **SIDE EFFECTS:**

- Fever
- Bruising
- Oozing of blood

#### **HOW SUPPLIED:**

- 25,000 units in 500 mL 0.45% NS (50u/mL)
- 25,000 units in 500mL  $D_5W$  (50u/mL)
- 25,000 units in 250mL D<sub>5</sub>W (100u/mL)
- 1,000 units in 500mL NS (2u/mL)

#### DOSE:

- 5,000 units (loading dose)
- Maintenance infusion is based on PTT results but is usually around 1,000 units/hr (dose will be determined by transferring facility)

#### **STANDING ORDERS:**

1. Any other change in rate/dosage of Heparin during interfacility transfer requires Medical Control order.

# Nitroglycerin

#### **CLASS:**

Nitrate

#### **ADDITIONAL NAMES:**

2. Nitrostat

#### **ACTION:**

- Vasodilator and vascular smooth muscle relaxant
- Reduces myocardial oxygen consumption, preload & afterload
- Metabolized by the liver
- Excreted in urine
- Half-life of 1-4 minutes
- IV onset of action immediate; duration variable

#### INDICATIONS:

- 1. Unstable angina pectoris if hemodynamically stable
- 2. Congestive heart failure (CHF) in settings of acute MI that are hemodynamically stable
- 3. Hypertensive emergencies

#### **CONTRAINDICATIONS:**

- 1. Sensitivity to nitrates
- 2. Increased ICP (e.g. head trauma, hemorrhagic stroke or other cerebral hemorrhage)
- 3. Uncorrected hypovolemia
- 4. Use of *erectile* dysfunction medications (Sildenafil-Viagra, Tadalafil-Cialis, Vardenadil-Levitra, or Avanafil-Stendra) within 48 hours

#### COMPLICATIONS/ADVERSE REACTIONS/SIDE EFFECTS:

- 1. Hypotension, especially postural (from vasodilation)
- 2. Dizziness/syncope (from hypotension)
- 3. Pallor/sweating (from hypotension)
- 4. Temporary pulsating headache (from vasodilation)
- 5. Nausea/vomiting
- 6. Tachycardia (in response to hypotension)
- 7. Paradoxical bradycardia (rare)
- 8. Rash or anaphylaxis

# Nitroglycerin

#### PRECAUTIONS:

Use with caution in the following patients:

- 1. Pregnant or lactating patients
- 2. Hepatic or renal disease
- 3. Pericarditis
- 4. Postural hypotension

#### **HOW SUPPLIED:**

- 25mg in 250mL D<sub>5</sub>W
- 50mg in 250mL D<sub>5</sub>W

**Note**: Nitroglycerin infusions MUST be in a glass bottle with **polyethylene tubing**.

#### DOSE:

• 5-50mcg/minute

- 1. Nitroglycerin infusion should have its own IV site. **No IV push drugs can be administered through this line**. If absolutely necessary, NTG is compatible with Heparin (and Lidocaine).
- 2. Titrate NTG drip to effect (patient's pain relief) by increasing in 10mcg increments every 3-5 minutes until a response is noted.
- 3. **BE ALERT FOR DEVELOPING HYPOTENSION**. Titrate down in 10mcg increments for hypotension. Monitor vital signs every 3-5 minutes after an increase in dose.
- 4. **Notify Medical Control** in the following circumstances
  - a. Chest pain re-occurs en route
  - **b.** Vital signs deviate from the predetermined parameters set forth by the transferring hospital
  - c. Any titration of the NTG drip (up or down)
- 5. Maximum infusion of NTG not to exceed 50mcg/minute

## Amiodarone

#### **CLASS:**

3. Class III antiarrhythmic

#### **ADDITIONAL NAMES:**

4. Cardone

#### **ACTION:**

5. Prolongs the duration of action potential and effective refractory period. Noncompetitive alphas and Beta-adrenergic inhibition. It increases the PR and QT intervals and decreases sinus rate. Also effective for atrial arrhythmias in patients with impaired left ventricular function when digoxin has proven ineffective.

#### **INDICATION:**

1. Treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia.

#### **CONTRAINDICATION:**

- 1. Known hypersensitivity.
- 2. Cardiogenic shock.
- 3. Marked Sinus Bradycardia and 2<sup>nd</sup> and 3<sup>rd</sup> heart block without functioning pacemaker.
- 4. Severe liver disease.
- 5. Hypotension.

#### **COMPLICATIONS/ADVERSE REACTIONS:**

#### Cardiovascular

- 1. Vasodilation and hypotension
- 2. Torsades de Pointes
- 3. Sinus arrest
- 4. Bradycardia
- 5. CHF
- 6. Prolonged QT interval
- 7. Negative inotropic effects

### Amiodarone

#### **Pulmonary**

- 1. Pulmonary toxicity
- 2. Progressive dyspnea
- 3. Fatigue
- 4. Cough
- 5. Pleuritic pain
- 6. Fever
- 7. Pulmonary edema

#### **PRECAUTIONS:**

- 1. Use with caution in renal failure patients
- 2. Incompatible with Heparin Sodium

#### **HOW SUPPLIED:**

- 150mg/3 mL
- 150mg/ 100 mL D5W
- 360 mg/ 100 mL D5W

#### DOSE:

- Loading dose of 150 mg or 300 mg infusion to be completed at transferring facility.
- Slow infusion of 360 mg over 6 hours at 1 mg/ min.
- Maintenance infusion of 540 mg over 18 hours at 0.5 mg/ min.

- 1. Verify Potassium, Magnesium and liver function labs, if available.
- 2. Notify Medical Control if heart rate less than 60 or B/P less than 90.

## Diltiazem

#### **CLASS:**

6. Calcium Channel Blocker

#### **ADDITIONAL NAMES:**

7. Cardizem

#### **ACTION:**

8. Inhibits calcium ion influx across the cell membrane in cardiac and vascular smooth muscle. Produces relaxation of coronary vascular smooth muscle and dilates coronary arteries. Slows SA/AV node conduction and dilates peripheral arteries.

#### INDICATION:

- 1. Atrial fibrillation with rapid ventricular response
- 2. Atrial Flutter
- 3. PSVT
- 4. Chronic unstable angina pectoris

#### **CONTRAINDICATION:**

- 1. 2<sup>nd</sup> or 3<sup>rd</sup> heart bock
- 2. Cardiogenic shock
- 3. Sick Sinus Syndrome
- 4. Hypotension of 90mmHg Systolic
- 5. Wolff-Parkinson-White Syndrome

#### **COMPLICATIONS/ADVERSE REACTIONS:**

#### Cardiovascular

- 1. Hypotension
- 2. CHF
- 3. Ventricular or atrial arrhythmias
- 4. Chest pain
- 5. Junctional or AV dissociation
- 6. Facial Flushing

### Diltiazem

#### **Central Nervous System**

- 1. Dizziness
- 2. Paresthesia
- 3. Headache
- 4. Weakness
- 5. Visual disturbance

#### **Dermatologic**

- 1. Injection site reaction (itching, burning)
- 2. Sweating

#### SIDE EFFECTS:

- 1. Constipation
- 2. Nausea
- 3. Vomiting
- 4. Dry Mouth

#### **HOW SUPPLIED:**

- 25mg/ 5 mL
- 100mg/ 100mL NS
- 100mg/100mL D5W

#### **DOSE:**

- 0.25mg/kg IVP over 2 minutes with second dose (if no response after fifteen minutes) of 0.35 mg/kg over 2 minutes to be given at transferring facility.
- 5-15 mg/hr (dose will be determined by transferring facility)

# Metoprolol (IVP)

#### **CLASS:**

Beta blocker

#### **ACTION(S):**

• Competitively blocks beta-1 receptors

#### **INDICATIONS:**

- 1. Atrial fibrillation/flutter, rate control
- 2. Hypertension

#### **CONTRAINDICATIONS:**

#### Absolute:

- 1. Hypersensitivity or allergy to metoprolol or other beta blocker medications
- 2. Second- or third-degree heart block
- 3. Sick sinus syndrome
- 4. Bradycardia
- 5. Hypotension

#### Relative:

1. Vasospastic angina

#### **COMPLICATIONS/ADVERSE REACTIONS:**

- 1. Bradyarrhythmia
- 2. Bronchospasm
- 3. Fatigue
- 4. Potentiation/masking of hypoglycemia

#### **PRECAUTIONS:**

Use caution when administering to those with past medical history of the following conditions:

- 1. Heart failure with reduced ejection fraction
- 2. Asthma or other obstructive respiratory disease
- 3. Myasthenia gravis
- 4. Pheochromocytoma
- 5. Thyroid disease
- 6. Diabetes
- 7. Hepatic impairment
- 8. Psoriasis
- 9. SVT

## Metoprolol

#### **SIDE EFFECTS:**

- Bradycardia
- Hypotension

#### **HOW SUPPLIED:**

- Solution, Intravenous, as tartrate:
  - o Generic: 5mg/5mL (5 mL)

#### DOSE:

- Atrial fibrillation/flutter, rate control
  - o 2.5mg to 5mg over 2 minutes; repeat dose every 5 min as needed; max total dose 15mg
- Hypertension
  - o 2.5mg to 5mg over 2 minutes; repeat dose every 5 min as needed; max total dose 15mg

### STANDING ORDERS:

1. Any other change in rate/dosage of metoprolol during interfacility transfer requires **Medical Control** order.

Table of Contents Section Table of Contents 42.N.2

# Magnesium Sulfate

#### **CLASS:**

Antidysrhythmic

#### **ACTION:**

9. Parenterally, magnesium decreases acetylcholine in motor nerve terminals and acts on myocardium by slowing rate of S-A node impulse formation and prolonging conduction time. Magnesium is necessary for the movement of calcium, sodium, and potassium in and out of cells, as well as stabilizing excitable membranes. Intravenous magnesium may improve pulmonary function in patients with asthma; causes relaxation of bronchial smooth muscle independent of serum magnesium concentration.

#### **INDICATION:**

- 1. Asthma/COPD, severe acute exacerbations
- 2. Eclampsia/preeclampsia with severe features
- 3. Hypomagnesemia
- 4. Torsades de pointes

#### **CONTRAINDICATION:**

- 1. Heart block
- 2. Myocardial damage

#### **COMPLICATIONS/ADVERSE REACTIONS:**

#### Cardiovascular:

- 1. Flushing
- 2. Hypotension
- 3. Vasodilation

#### Endocrine and metabolic:

1. Hypermagnesemia - Magnesium toxicity can lead to fatal cardiovascular arrest and/or respiratory paralysis

#### **PRECAUTIONS:**

- 1. Use with extreme caution in patients with history of myasthenia gravis or other neuromuscular disease
- 2. Caution in patients with renal impairment (risk of build-up causing Magnesium toxicity)

# Magnesium Sulfate

#### **HOW SUPPLIED:**

- Solution, Injection:
  - o Generic: 50% (10 mL, 20 mL)
- Solution, Injection [preservative free]:
  - o Generic: 50% (2 mL, 10 mL, 20 mL, 50 mL)
- Solution, Intravenous:
  - o Generic: 4 g/100 mL (100 mL); 1 g/100 mL (100 mL); 2 g/50 mL (50 mL); 20 g/500 mL (500 mL); 4 g/50 mL (50 mL); 40 g/1000 mL (1000 mL)
- Solution, Intravenous [preservative free]:
  - Generic: 4 g/100 mL (100 mL); 1 g/100 mL (100 mL); 2 g/50 mL (50 mL); 20 g/500 mL (500 mL); 4 g/50 mL (50 mL); 40 g/1000 mL (1000 mL)

#### DOSE:

- Asthma/COPD severe acute exacerbation:
  - o IV: 2 g as a single dose over 20 minutes
- Eclampsia/preeclampsia with severe features:
  - O IV: Initial: 4 to 6 g loading dose over 15 to 30 minutes at onset of labor or induction/cesarean delivery, followed by 1 to 2 g/hour continuous infusion for at least 24 hours after delivery; maximum infusion rate: 3 g/hour.
    - If seizure occurs while receiving magnesium, an additional bolus of 2 to 4 g may be administered over ≥5 minutes with frequent monitoring for toxicity
- Hypomagnesemia:
  - o IV: slowly administer at rate ≤1 g/hour
- Torsades de pointes:
  - Polymorphic ventricular tachycardia (with pulse) associated with QT prolongation (torsades de pointes):
    - IV: 1 to 2 g (diluted in 50 to 100 mL D5W) over 15 minutes (range: 5 to 60 minutes)
    - If no response or torsades de pointes recurs, may repeat dose up to a total of 4 g in 1 hour
  - Ventricular fibrillation/pulseless ventricular tachycardia associated with torsades de pointes: Note: Administer in conjunction with electrical cardioversion/defibrillation.
    - **IV/intraosseous:** 1 to 2 g (diluted in 10 mL D5W) administered as a bolus over ≥1 to 2 minutes; if ineffective, may repeat immediately; maximum total dose: 6 g

### Octreotide

#### **CLASS:**

- Synthetic hormone
- Antidiarrheal Somatostatin Analog

#### **Additional Names**

Sandostatin

#### **ACTION(S):**

• Long Acting octapeptide with pharmacologic actions mimicking those of the natural hormone somatostatin

#### INDICATIONS:

- 1. GI Bleed
- 2. Refractory hypoglycemia in combination with Dextrose

#### **CONTRAINDICATIONS:**

#### **Absolute:**

- 1. Known allergy to Octreotide
- 2. Patients with known Bradycardia or ECG changes and arrhythmias
- 3. Dialysis

#### Relative:

- 1. Dosage may be reduced for renal failure/ dialysis patients
- 2. Patients with known bradycardia or ECG changes/ arrhythmias

#### **COMPLICATIONS/ADVERSE REACTIONS:**

1. May affect insulin dosing

#### **PRECAUTIONS:**

Use with caution in the following patients:

- 1. May enhance toxicity of QTc prolonging agents
- 2. Multiple drug incompatibilities

## Octreotide

#### **SIDE EFFECTS:**

- Abdominal or stomach pain
- Blurred vision
- Dizziness
- Dry mouth
- Fainting
- Fast, slow, or irregular heartbeat
- Flushed, dry skin
- Muscle cramps and stiffness
- Nausea
- Severe stomach pain with nausea and vomiting
- Sweating
- Hyperglycemia

#### **HOW SUPPLIED:**

• 500 mcg/100 mL

#### DOSE:

• 25-100 mcg/hr

- 1. Verify lab values (platelet count, coagulation studies) prior to departure (if available).
- 2. If uncontrolled bleeding or allergic reaction develops, immediately discontinue the infusion, provide necessary treatment and **contact Medical Control**.

# Hydrocortisone Sodium succinate

#### **CLASS:**

• Glucocorticoid

#### **ACTION(S):**

• Acts on glucocorticoid receptors similar to cortisol

#### **INDICATIONS:**

- 1. Adrenal insufficiency/crisis
- 2. Septic shock
- 3. Thyroid storm

#### **CONTRAINDICATIONS:**

#### Absolute:

- 1. Hypersensitivity
- 2. Systemic fungal infections
- 3. Premature infants
- 4. Idiopathic thrombocytopenia purpura

#### **COMPLICATIONS/ADVERSE REACTIONS:**

- 1. Arrhythmia (bradycardia)
- 2. Rash
- 3. Hypersensitivity reaction
- 4. Pulmonary edema
- 5. Psychosis

### PRECAUTIONS:

- 1. Avoid extravasation as can be damaging to local tissues
- 2. Can cause psychiatric disturbances such as insomnia, personality changes up to acute psychosis

#### **SIDE EFFECTS:**

- Rash
- Pulmonary edema
- Insomnia
- Acute psychosis

# Hydrocortisone Sodium succinate

#### **HOW SUPPLIED:**

Intravenous

#### DOSE:

- Adrenal Insufficiency
  - o Adults:
    - 100 mg IV bolus (initial dose), followed by 50 mg Q6H
  - o Peds
    - 2-3 mg/kg IV loading dose (max 100 mg), followed by 1-5 mg/kg Q6H (infants), 25-50 mg/day divided into 4 doses (1-5 years), 50-100 mg/day divided into 4 doses (5-adolescent)
- Thyroid Storm
  - Adults
    - 300 mg IV loading dose, followed by 100 mg Q8H

#### **STANDING ORDERS:**

1. Any other change in rate/dosage during interfacility transfer requires **Medical Control** order.

## Furosemide

#### **CLASS:**

Diuretic

#### **ACTION(S):**

• Acts on Na/K/Cl channel in renal tubules

#### **INDICATIONS:**

- 1. Congestive Heart Failure
- 2. Anasarca
- 3. Volume Overload

### **CONTRAINDICATIONS:**

#### **Absolute:**

- 1. Hypersensitivity reaction
- 2. History of sulfa allergy
- 3. Hypotension
- 4. Volume depletion
- 5. Cirrhosis

#### **COMPLICATIONS/ADVERSE REACTIONS:**

- 2. Hypersensitivity reaction
- 3. Volume depletion
- 4. Hypotension
- 5. Acute kidney injury
- 6. Ototoxicity

#### **PRECAUTIONS:**

- 1. Avoid using in patients with suspected dehydration
- 2. Patients who have an allergic reaction to sulfa drugs are at increased risk for allergic reaction to furosemide

## **Furosemide**

#### **SIDE EFFECTS:**

- Dizziness
- Abdominal cramping
- DRESS syndrome
- Headache
- Vertigo

#### **HOW SUPPLIED:**

• IV

#### **DOSE:**

- Adult
  - 20-80 mg IV push 1-2x per day
- Pediatric
  - o 2 mg/kg as single dose

#### STANDING ORDERS:

1. Any other change in rate/dosage during interfacility transfer requires Medical Control order.



## Pantoprazole

#### **CLASS:**

10. Proton Pump Inhibitor

#### **ADDITIONAL NAMES:**

11. Protonix

#### **ACTION:**

12. Decreases secretion of gastric acid and chronic reflux

#### **INDICATION:**

1. Patients with Upper GI Bleed

#### **CONTRAINDICATION:**

1. Allergy to drug or drug class

#### **COMPLICATIONS/ADVERSE REACTIONS:**

- 1. Jaundice
- 2. GI upset
- 3. CNS Symptoms in elderly

#### PRECAUTIONS:

1. Hypersensitivity to Proton Pump Inhibitor drug class.

#### **SIDE EFFECTS:**

- Anaphylaxis
- Rash

#### **HOW SUPPLIED:**

- 40 mg/50 mL
- 80 mg/ 100 mL

#### DOSE:

- Bolus of 80 mg over 5 minutes given prior to infusion.
- IV Infusion of 8 mg/ hour.

# Multivitamin Banana Bag

#### Class

• Vitamin

#### **OTHER NAMES:**

Rally Packs

#### **ACTION(S):**

• Replenishes vitamins/ minerals and fluids lost in acute alcohol consumption.

#### **INDICATIONS:**

1. Vitamin and electrolyte deficiencies in chronic alcohol consumption

#### **CONTRAINDICATIONS:**

#### **Absolute:**

1. True allergy to any component of the preparation

### **COMPLICATIONS/ADVERSE REACTIONS:**

None

#### PRECAUTIONS:

Use with caution in the following patients:

1. May not provide sufficient quantities of Thiamine for patient with Wernicke's Encephalopathy

#### **SIDE EFFECTS:**

None

#### **EQUIPMENT:**

May run to gravity


# Multivitamin Banana Bag

#### **HOW SUPPLIED:**

- 1 L 0.9% Normal Saline
  - o 1 amp multivitamin
  - o 1 mg Folate
  - o 100 mg Thiamine
  - o In some situations Magnesium is added
    - Dose may vary, typically 3g
    - If Magnesium is added, must be run by IV pump

#### **DOSE:**

• 1 L over 2 or more hours



## Sodium Bicarbonate

#### **CLASS:**

• Alkalizing agent

#### **ACTION(S):**

- Sodium Bicarbonate acts as a buffer working to restore normal plasma pH levels.
- Excess hydrogen ions react with bicarbonate resulting in the formation of carbon dioxide and water

#### **INDICATIONS:**

- 1. Metabolic Acidosis
- 2. Rhabdomyolysis
- 3. Certain Overdoses (Salicylate and Tricyclic antidepressant)

#### **CONTRAINDICATIONS:**

1. Use with caution in patients with CHF, severe renal insufficiency and hypertension.

#### **PRECAUTIONS:**

- 1. Monitor IV site and patency to avoid extravasation.
- 2. Stop infusion and contact Medical Control if extravasation.
- 3. Extravasation should also be directly reported to receiving provider.

#### **SIDE EFFECTS:**

Elevated sodium

#### **HOW SUPPLIED:**

• 150 mEq/L (3 ampules of NaHCO3 mixed in 1 L D5W)

#### DOSE:

• Typical infusion rate of 100 -250 mL/hour

- 1. ETCO2 monitoring required throughout transport.
- 2. Not a titratable medication
- 3. Hold infusion for signs and symptoms of decompensated CHF and contact Medical Control
- 4. Contact Medical Control for infusion rate > 250 mL/hour.

## Vitamin K

#### **CLASS:**

• Fat soluble vitamin class

#### **ACTION(S):**

• Promotes liver synthesis of clotting factors (II, VII, IX, X)

#### **INDICATIONS:**

1. Reversal of anticoagulation due to warfarin

#### **CONTRAINDICATIONS:**

#### **Absolute:**

1. Hypersensitivity to Vitamin K medication or any component of the formulation

#### **COMPLICATIONS/ADVERSE REACTIONS:**

Fatal hypersensitivity reactions, including anaphylaxis, have occurred during and immediately
after IV and IM injection of phytonadione. Reactions have occurred despite dilution to avoid
rapid IV infusion and upon first dose. Avoid the IV and IM routes of administration unless the
SUBQ route is not feasible, and the serious risk is justified.

#### **PRECAUTIONS:**

1. Due to risk of a severe infusion reaction, including anaphylaxis, the maximum rate of IV administration is 1 mg/minute.

#### **SIDE EFFECTS:**

- Dermatologic toxicity
- Hypersensitivity/anaphylactoid reactions

# Vitamin K

#### **HOW SUPPLIED:**

• Injection: 1mg/0.5mL (0.5mL); 10mg/mL (1mL)

• Tablet: 100mcg; 5mg

#### DOSE:

- Oral: Initial: 2.5 to 10 mg, depending on the INR. Administer as a single dose. Measure INR after 12 to 48 hours and administer another dose as needed.
- IV: Initial: 2.5 to 10 mg, depending on the INR and severity of bleeding. Administer as a single dose over 10 to 20 minutes (maximum infusion rate: 1 mg/minute). Measure INR after 6 to 12 hours and administer another dose as needed.

#### **STANDING ORDERS:**

1. Any other change in rate/dosage of Vitamin K during interfacility transfer requires **Medical Control** order.